These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35739516)

  • 21. Trends in premature avertable mortality from non-communicable diseases for 195 countries and territories, 1990-2017: a population-based study.
    Martinez R; Lloyd-Sherlock P; Soliz P; Ebrahim S; Vega E; Ordunez P; McKee M
    Lancet Glob Health; 2020 Apr; 8(4):e511-e523. PubMed ID: 32199120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure.
    Buse K; Tanaka S; Hawkes S
    Global Health; 2017 Jun; 13(1):34. PubMed ID: 28619031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-communicable diseases in the southwest of Iran: profile and baseline data from the Shahrekord PERSIAN Cohort Study.
    Ahmadi A; Shirani M; Khaledifar A; Hashemzadeh M; Solati K; Kheiri S; Sadeghi M; Mohammadian-Hafshejani A; Shahraki HR; Asgharzadeh A; Salehifard AZ; Mousavi M; Zarean E; Goujani R; Nazari SSH; Poustchi H; Dugué PA
    BMC Public Health; 2021 Dec; 21(1):2275. PubMed ID: 34903205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review on Noncommunicable Diseases (NCDs) burden, its socio-economic impact and the strategies for prevention and control of NCDs in India.
    Kundu MK; Hazra S; Pal D; Bhattacharya M
    Indian J Public Health; 2018; 62(4):302-304. PubMed ID: 30539894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Population Level and Individual Level Interventions to Combat Non-communicable Disease in Eastern Sub-Saharan Africa and South East Asia: A WHO-CHOICE Analysis.
    Bertram MY; Chisholm D; Watts R; Waqanivalu T; Prasad V; Varghese C
    Int J Health Policy Manag; 2021 Nov; 10(11):724-733. PubMed ID: 34273918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-communicable Diseases Week: Best Practices in Addressing the NCDs Burden from Tanzania.
    Njiro BJ; Ngowi JE; Ndumwa HP; Amani D; Munishi C; Mloka D; Balandya E; Rugajo P; Kessy AT; Ubuguyu O; Salum B; Kamuhabwa A; Ramaiya K; Sunguya BF; Mboya EA; Kikula AI; Kitambala E; Kiologwe J; Kengia JT; Kapologwe N
    Ann Glob Health; 2023; 89(1):89. PubMed ID: 38107601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International investment liberalization, transnational corporations and NCD prevention policy non-decisions: a realist review on the political economy of tobacco, alcohol and ultra-processed food.
    Milsom P; Smith R; Baker P; Walls H
    Global Health; 2021 Nov; 17(1):134. PubMed ID: 34819083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The financial burden of non-communicable diseases in the European Union: a systematic review.
    Vandenberghe D; Albrecht J
    Eur J Public Health; 2020 Aug; 30(4):833-839. PubMed ID: 31220862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The current situation and agendas in the prevention and control of non-communicable diseases in Vietnam].
    Hattori K; Uda H; Hitomi Y; Yano R; Saijo T; Watanabe N; Satomi M; Yoshida A; Oishi O; Yamashita T; Kamenosono A
    Nihon Koshu Eisei Zasshi; 2018; 65(4):170-178. PubMed ID: 29731483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries.
    NCD Countdown 2030 collaborators
    Lancet; 2022 Mar; 399(10331):1266-1278. PubMed ID: 35339227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of noncommunicable diseases on direct medical costs and worker productivity, Saudi Arabia.
    Malkin J; Finkelstein E; Baid D; Alqunaibet A; Almudarra S; Herbst CH; Dong D; Alsukait R; El-Saharty S; Algwizani A
    East Mediterr Health J; 2022 Apr; 28(4):296-301. PubMed ID: 35545911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The macroeconomic burden of noncommunicable diseases in the United States: Estimates and projections.
    Chen S; Kuhn M; Prettner K; Bloom DE
    PLoS One; 2018; 13(11):e0206702. PubMed ID: 30383802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative financing analysis and political economy of noncommunicable diseases.
    Jakovljevic M; Jakab M; Gerdtham U; McDaid D; Ogura S; Varavikova E; Merrick J; Adany R; Okunade A; Getzen TE
    J Med Econ; 2019 Aug; 22(8):722-727. PubMed ID: 30913928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-communicable diseases and health systems reform in low-and-middle-income countries.
    Robinson HM; Hort K
    Pac Health Dialog; 2012 Apr; 18(1):179-90. PubMed ID: 23240355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline status of policy and legislation actions to address non communicable diseases crisis in the Pacific.
    Win Tin ST; Kubuabola I; Ravuvu A; Snowdon W; Durand AM; Vivili P; Passmore E
    BMC Public Health; 2020 May; 20(1):660. PubMed ID: 32398159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the Cost of Delivering Tobacco Cessation Intervention Package at Noncommunicable Disease Clinics in Two Districts of North India.
    Bhatt G; Goel S; Kiran T; Grover S; Medhi B; Singh G; Singh Gill S
    Nicotine Tob Res; 2023 Sep; 25(11):1727-1735. PubMed ID: 37402314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of tobacco cessation intervention at non-communicable diseases clinics: A qualitative study from a North Indian State.
    Bhatt G; Goel S; Grover S; Medhi B; Jaswal N; Gill SS; Singh G
    PLoS One; 2023; 18(5):e0284920. PubMed ID: 37141319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The protocol of a population-based prospective cohort study in southwest of Iran to analyze common non-communicable diseases: Shahrekord cohort study.
    Khaledifar A; Hashemzadeh M; Solati K; Poustchi H; Bollati V; Ahmadi A; Kheiri S; Samani KG; Banitalebi M; Sedehi M; Malekzadeh R
    BMC Public Health; 2018 May; 18(1):660. PubMed ID: 29801446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in premature mortality in the Islamic Republic of Iran: probability of dying between ages 30 and 70 years.
    Kazemi E; Khosravi A; Aghamohamadi S; Shariati M; Kazemeini H
    East Mediterr Health J; 2021 Jan; 27(1):33-40. PubMed ID: 33538317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intersectoral collaboration in the management of non-communicable disease's risk factors in Iran: stakeholders and social network analysis.
    Bakhtiari A; Takian A; Majdzadeh R; Ostovar A; Afkar M; Rostamigooran N
    BMC Public Health; 2022 Sep; 22(1):1669. PubMed ID: 36056315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.